Gliclashield-M 80 Tablet is a fixed-dose combination medication containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and increasing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The combination of these two agents provides complementary mechanisms of action, offering effective control of blood glucose levels in patients inadequately managed by diet, exercise, or monotherapy. Gliclashield-M 80 is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust dosing and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Contraindications include renal impairment, hepatic dysfunction, and conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances and hypoglycemia. Patient adherence and periodic evaluation of renal function and glycemic parameters are essential to ensure therapeutic efficacy and safety during treatment with Gliclashield-M 80 Tablet.

Dosage & How to Use